Evidence map›Paper›PMID 42608566›Full record

ArticleNature biotechnology2026

Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.

Hyuncheol Jung, Pascal Devant, Carter Ching, Mineto Ota, Emma Dann, Ronghui Zhu, Chandrima Modak, Ana Vasquez-Ibarra, Jennifer R Hamilton, Zachary Steinhart and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Hyuncheol Jung *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Pascal Devant *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Carter ChingDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0009-0008-9117-3025
Mineto OtaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4552-8573
Emma DannGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Ronghui ZhuGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Chandrima ModakGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Ana Vasquez-IbarraGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Jennifer R HamiltonInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7136-1757
Zachary SteinhartGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Wayne NgoInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-5755-2303
Luis SandovalDepartment of Medicine, University of California, San Francisco, CA, USA.
Jae Hyung JungDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0009-0009-2998-5249
Jae Hyun J LeeGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Da XuDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0000-0003-1633-9503
Meirui AnMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4006-8670
Esha UrsDepartment of Medicine, University of California, San Francisco, CA, USA.
Peixin Amy ChenDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9930-1249
Vincent AllainGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Takuya TadaDepartment of Microbiology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-0779-9954
Luke A GilbertUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Brian R ShyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9569-3708
Jonathan K PritchardDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8828-5236
James K NuñezDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7396-6119
Nathaniel R LandauDepartment of Microbiology, NYU Grossman School of Medicine, New York, NY, USA.
David R LiuMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Justin EyquemGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8262-1190
Jennifer A DoudnaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9161-999X
Alexander MarsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. Alexander.Marson@ucsf.edu.ORCID http://orcid.org/0000-0002-2734-5776
Julia CarnevaleGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. Julia.Carnevale@ucsf.edu.ORCID http://orcid.org/0000-0001-9410-7148

Funding

National Research Foundation of Korea (NRF) RS-2023-00242661
6 · The paper itself

Abstract

Primary human myeloid cells hold promise for immunotherapies, yet efficient, scalable technologies for engineering and screening in these cells remain limited. Here we present a virus-like particle (VLP)-based toolkit that delivers diverse CRISPR editing modalities to human monocytes, macrophages and dendritic cells with high efficiency while preserving viability and innate immune responsiveness. VLP-mediated delivery of ribonucleoproteins supports gene knockout, base editing and epigenetic silencing. Combined with adeno-associated virus-mediated donor delivery, this approach enables site-specific integration of large DNA sequences by homology-directed repair. We developed SLICeVLP, which pairs sgRNA delivery by VPX-lentivirus with Cas9 protein delivery by engineered VLPs, and used it for pooled loss-of-function and Perturb-seq screens in human macrophages. We uncovered regulators of tumor necrosis factor (TNF) and CD80 expression, converging on TNFAIP3 as a central regulator of inflammatory polarization. TNFAIP3 ablation drove a proinflammatory state resistant to suppressive repolarization and enhanced cytotoxicity in chimeric antigen receptor macrophages. This system enables unbiased functional genomics in primary human myeloid cells, with implications for myeloid cell therapy design.

Identifiers

PMID42608566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.